Abstract
Drug therapy mistreatment, undertreatment and overtreatment of older persons are prevalent. Given the pharmacokinetic and pharmacodynamic changes in seniors, the risk versus benefit of treatment should be weighed before implementing pharmacotherapy. Clinicians cannot rely exclusively on high-quality scientific evidence to make treatment decisions, given the paucity of evidence-based approaches to care in this population. A growing emphasis is needed, by pharmaceutical companies and independent researchers, to understand the value of treatment in older persons. An examination of the evidence for treatment of depression Alzheimer’s disease, behavioral symptoms of dementia and depression in older persons is presented. Further research in this growing and highly vulnerable population is needed to guide informed treatment decisions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
